• Superior Survival With Sintilimab in Squamous NSCLC

    4 days ago - By Medscape

    Second-line treatment with sintilimab improved survival compared with docetaxel in patients with advanced/metastatic squamous nonsmall cell lung cancer in the phase 3 ORIENT-3 trial.
    Medscape Medical News
    Read more ...